NeoPredics - Investor Relations US

INVESTOR RELATIONS

Please contact us anytime: This email address is being protected from spambots. You need JavaScript enabled to view it.

Predictive Neonatal Clinical Decicion Support Platform

Why invest in NeoPredics?

Software-as-a-Service
Digital Health
Breakthrough prediction tool
Global market potential
Dedicated team of scientific and market experts

Investor Calender

NeoPredics will present at the following conferences

Investor Media Center

Thorsten Waloschek Presents NeoPredics at LSI USA ’23 (Youtube)

Mayo Clinic Platform_Accelerate: NeoPredics (external link to Youtube)

PRESS RELEASES

Multi-Center Observational Study

Clinical Decision Support Company NeoPredics AG Completes Prospective Multi-Center Observational Study

Basel, Switzerland, Regensburg, Germany, and Ft. Lauderdale, FL, USA, May 25, 2022 – NeoPredics AG, a privately held maternal and neonatal clinical decision support company focused on the development and commercialization of intelligent algorithms to predict dynamic progression of disease parameters during the first 1,000 days of life, announced at a poster presentation during the recent 48th Annual Meeting of the German Society for Neonatology and Pediatric Intensive Medicine held in Aachen, Germany, that a prospective multi-center observational study was formally completed.

Investment from Springhood Ventures

NeoPredics Secures Investment from Springhood Ventures to Advance Neonatal Health Innovations

Fort Lauderdale, FL - NeoPredics, a leading predictive analytics company focused on neonatal, maternal, and perinatal health, is pleased to announce an investment from Springhood Ventures. This investment will further accelerate the development and deployment of NeoPredics's innovative solutions aimed at improving outcomes for newborns worldwide.

COVERAGE BY COMPANYGLANCE

Coverage on NeoPredics by companyglance.com

Coverage on NeoPredics by companyglance.com: NeoPredics: Revolutionizing Maternal And Neonatal Care With Predictive Analytics (Published: Sep 16, 2024)

Cairman of the Board

NeoPredics Welcomes Todd Usen as Chairman of the Board

NeoPredics AG Germany and NeoPredics USA Inc., is pleased to announce the appointment of Mr. Todd Usen as Chairman of the Board, marking an exciting new chapter for the company as it continues to grow its impact in maternal and neonatal healthcare.

Start-up company opens first US office

NeoPredics starts marketing its prediction software platform in USA

November 15, 2021 - With the establishment of NeoPredics USA in Fort Lauderdale (Florida) the German/Swiss NeoPredics AG starts its US business and pushes its internationalization strategy. The start-up company develops prediction software for hospitals and neonatal units based on scientific and clinical data as well as science-based algorithms.

NeoPredics PRESENT AT BIOTECH SHOWCASE™ 2022

Breakthrough Prediction Software Platform of NeoPredics shown at BIOTECH SHOWCASE

Regensburg, Germany. 22nd of December 2021 – NeoPredics today announced that it will be presenting virtually at the Biotech Showcase™ 2022 conference with an online presentation.

Who is NeoPredics

NeoPredics AG test is a Swiss company located in Basel with subsidiaries in Regensburg, Germany and Ft. Lauderdale, Florida, USA.

Contact us

Please feel free to contact us at any time for further questions and requests.
This email address is being protected from spambots. You need JavaScript enabled to view it.